Randomized, Open-label, Crossover Study to Evaluate the Effect of Genetic Polymorphism on Pharmacokinetic and Pharmacodynamic Interactions of Clopidogrel and Cilostazol in Korean Healthy Adult Volunteers.

Trial Profile

Randomized, Open-label, Crossover Study to Evaluate the Effect of Genetic Polymorphism on Pharmacokinetic and Pharmacodynamic Interactions of Clopidogrel and Cilostazol in Korean Healthy Adult Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 31 May 2017

At a glance

  • Drugs Cilostazol (Primary) ; Clopidogrel (Primary)
  • Indications Acute coronary syndromes; Angina pectoris; Arterial occlusive disorders; Atherosclerosis; Cardiovascular disorders; Intermittent claudication; Ischaemic heart disorders; Myocardial infarction; Peripheral arterial occlusive disorders; Stroke
  • Focus Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 09 Mar 2013 Results presented at the 114th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
    • 06 Jun 2012 New source identified and integrated (Korean Clinical Trials Register KCT0000443).
    • 06 Jun 2012 Actual end date (Jan 2012) added as reported by Korean Clinical Trials Register record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top